The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.
|Articles|November 6, 2006
Once-daily beta-blocker OK'd for three indications
Advertisement
Carvedilol extended-release capsules (Coreg CR, GlaxoSmithKline), a new once-daily third-generation beta-blocker, has received FDA approval for three indications. The capsule utilizes Flamel Technologies' proprietary Micropump technology, which controls the release of drug from the capsule over 24 hours. Coreg CR can be used to treat hypertension, post-myocardial infarction left ventricular dysfunction, and mild to severe heart failure. According to Glaxo, shipments will begin in the first quarter of 2007.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.
An American Heart Association scientific statement shows earlier risk factors and social barriers driving cardiovascular disparities in Hispanic adults.
In an exploration of 2 distinct timeframes in the 21st century, researchers examine the use and concurrent use of medication types among elderly US adults.
The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Tozorakimab Reduces COPD Exacerbations in Phase 3 Trials
3
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
4
Polypharmacy, Drug Interactions Threaten Older Adults’ Medication Safety
5